Omada Health is trading 5.04% up now at $20.69, though the rebound’s immediate catalyst remains unclear.
- On September 11, shares fell 8.56% to $19.66.
- The September 10 Investor Day outlined long-term targets of at least 20% annual revenue growth, 80% non-GAAP gross margin, and 30% adjusted EBITDA margin.
- September 11 coverage showed Barclays maintaining and Needham reiterating views; no clear company-specific announcement or analyst action dated September 14 was identified.